CD163 overexpression
|
HL
|
CD163 overexpression
|
HL
|
nivolumab + brentuximab vedotin Sensitive: C3 – Early Trials
|
nivolumab + brentuximab vedotin Sensitive: C3 – Early Trials
|
CD163 overexpression
|
Solid Tumor
|
CD163 overexpression
|
Solid Tumor
|
avelumab + eftilagimod alpha Sensitive: C3 – Early Trials
|
avelumab + eftilagimod alpha Sensitive: C3 – Early Trials
|
CD163 overexpression
|
Solid Tumor
|
CD163 overexpression
|
Solid Tumor
|
eftilagimod alpha Sensitive: C3 – Early Trials
|
eftilagimod alpha Sensitive: C3 – Early Trials
|